Adial Pharmaceuticals, Inc.
ADIL
$0.6565
-$0.0183-2.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.37% | 2.52% | 21.69% | -26.93% | -26.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.80% | 62.86% | 54.81% | -18.68% | -31.33% |
| Operating Income | -8.80% | -62.86% | -54.81% | 18.68% | 31.33% |
| Income Before Tax | -8.74% | -62.63% | -62.81% | -189.15% | 25.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.74% | -62.63% | -62.81% | -189.15% | 25.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 94.98% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.84% | -58.25% | -325.99% | -122.89% | 33.01% |
| EBIT | -8.80% | -62.86% | -54.81% | 18.68% | 31.33% |
| EBITDA | -8.80% | -62.86% | -54.82% | 18.68% | 31.33% |
| EPS Basic | 60.75% | 68.04% | -161.13% | 20.13% | 70.46% |
| Normalized Basic EPS | -33.37% | 67.62% | 55.96% | 67.81% | 67.06% |
| EPS Diluted | 60.75% | 68.04% | -161.13% | 20.25% | 70.46% |
| Normalized Diluted EPS | -33.37% | 67.62% | 55.96% | 67.81% | 67.06% |
| Average Basic Shares Outstanding | 174.79% | 395.18% | 269.70% | 179.06% | 126.76% |
| Average Diluted Shares Outstanding | 174.79% | 395.18% | 269.70% | 179.06% | 126.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
